Skip to content

Author

Abigail Pinchbeck

We have 3 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Industry Insights: The adjuvant access problem: barriers to broader vaccine development

A cell therapy safety signal defined the month: Novartis paused eight trials of its experimental CAR-T therapy rap-cel across autoimmune and neurological indications after three deaths from immune effector cell-associated hemophagocytic syndrome, prompting Bristol Myers Squibb to pause a rival program as a precaution....

Abigail Pinchbeck · 0 citations
Jul 2026

Industry Insights: The first CAR-T approval in solid tumors and the FDA recalibrates

June delivered a landmark for the CAR-T field alongside a distinct shift in US regulatory posture. CARsgen secured NMPA approval for satri-cel, the first CAR-T cell therapy approved for a solid tumor indication anywhere in the world, targeting Claudin18.2 in advanced gastric and gastroesophageal junction adenocarcinoma...

Abigail Pinchbeck · 0 citations
Open access Aug 2026

Industry Insights: Expanding access across the field, from pediatric approvals to the first solid tumor CAR‑T

July 2026 saw the field push access outward on multiple fronts, from the first FDA approval of a genetic therapy for children as young as 2 years (Vertex’s CASGEVY) to the first international patient treated with satri‑cel, the first CAR‑T therapy approved anywhere for a solid tumor. Regulatory momentum extended across...

Abigail Pinchbeck · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.